Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG le...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Future oncology (London, England) England), 2022-03, Vol.18 (10), p.1235-1244
Hauptverfasser:	Yasin, Ayse Irem, Aydin, Sabin Göktas, Sümbül, Bilge, Koral, Lokman, Şimşek, Melih, Geredeli, Çağlayan, Öztürk, Akın, Perkin, Perihan, Demirtaş, Derya, Erdemoglu, Engin, Hacıbekiroglu, İlhan, Çakır, Emre, Tanrıkulu, Eda, Çoban, Ezgi, Ozcelik, Melike, Çelik, Sinemis, Teker, Fatih, Aksoy, Asude, Fırat, Sedat T, Tekin, Ömer, Kalkan, Ziya, Türken, Orhan, Oven, Bala B, Dane, Faysal, Bilici, Ahmet, Isıkdogan, Abdurrahman, Seker, Mesut, Türk, Hacı M, Gümüş, Mahmut
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Viral - blood cancer chemotherapy CoronaVac COVID-19 COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Female Humans immunotherapy Male malignancy Middle Aged Neoplasms - immunology Prospective Studies SARS-CoV-2 SARS-CoV-2 - immunology Vaccination Vaccines, Inactivated - adverse effects Vaccines, Inactivated - immunology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p
ISSN:	1479-6694 1744-8301
DOI:	10.2217/fon-2021-1248